Bicycle Therapeutics (BCYC) PT Lowered to $42 at Jefferies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. STX
3. KIDS
4. BA
5. HOOD
6. NXPI
7. CSGP
8. MANH
9. BKR
10. RCL

Go back to Bicycle Therapeutics (BCYC) PT Lowered to $42 at Jefferies

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025 7:00 AM EST

Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer; Duravelo-2 dose selection data expected in 2H 2025

Enhanced response to zelenectide pevedotin seen in NECTIN4 gene-amplified late-line breast cancer and non-small cell lung cancer (NSCLC), resulting in U.S. FDA Fast Track designations for triple-negative breast cancer and NSCLC; several Phase 1/2 trials expected to start in 2025

Advancing radiopharmaceuticals pipeline, with additional MT1-MMP human imaging data expected in mid-2025 and first EphA2... More